Search
lefamulin (Xenleta)
Indications:
- community-acquired pneumonia in adults [1,2]
Contraindications:
- not recommended during pregnncy
Dosage:
- oral (600 mg every 12 hours)
- intracenous (150 mg every 12 hours) [2]
Adverse effects:
- common
- diarrhea, nausea/vomiting, elevated liver enzymes
- prolonged QT interval
- cardiac arrhythmias [1]
Antimicrobial activity:
- Streptococcus pneumoniae
- Staphylococcus aureus (MSSA)
- Haemophilus influenzae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae [2]
Mechanism of action:
- semisynthetic pleuromutilin antibiotic
Notes:
- projected wholesale acquisition price:
- $205 per IV patient treatment day
- $275 per oral patient treatment day [2]
General
pleuromutilin; drosopholin B; pleuromulinum; pleuromulina; pleuromuline
Database Correlations
PUBCHEM correlations
References
- FDA News Release. Aug 19, 2019
FDA approves new antibiotic to treat community-acquired bacterial pneumonia.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia
- Brooks M
FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP.
Medscape - Aug 19, 2019.
https://www.medscape.com/viewarticle/917020
- Alexander E, Goldberg L, Das AF et al
Oral Lefamulin vs Moxifloxacin for Early Clinical Response
Among Adults With Community-Acquired Bacterial Pneumonia.
The LEAP 2 Randomized Clinical Trial.
JAMA. Published online September 27, 2019
PMID: 31560372
https://jamanetwork.com/journals/jama/fullarticle/2752331
- Malani PN
Lefamulin - A New Antibiotic for Community-Acquired Pneumonia.
JAMA. Published online September 27, 2019
PMID: 31560367
https://jamanetwork.com/journals/jama/fullarticle/2752330